SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing extreme volatility and heavy short-selling pressure, with investors aggressively debating whether the stock is undergoing a permanent collapse or a temporary shakeout after a rapid, parabolic run. Market participants are fixated on the frequent trading halts, the intense conflict between retail bulls looking for a bounce and shorts capitalizing on the sharp downside move, and broader concerns regarding the company's valuation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing intense community focus as traders debate its potential for a major breakout above the psychological $50 level, fueled by speculation surrounding unannounced hyperscaler partnerships and upcoming capacity energization. While bulls emphasize the company's expanding infrastructure moat and institutional accumulation, others remain cautious of volatility and potential dilution, keeping the stock at the center of a heated debate between AI-driven upside and short-term price manipulation concerns.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is currently trending due to intensifying speculation surrounding a potential shift in federal marijuana policy, with traders closely monitoring reports of a pending reclassification from Schedule I to Schedule III. Community discourse is highly polarized, as retail investors debate whether this development marks a sustainable shift toward long-term sector growth or if it is merely another volatile catalyst susceptible to a 'sell the news' reversal.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is seeing significant volatility and increased bullish sentiment following its latest quarterly update, which highlighted progress on pilot production and expansion into new markets like AI data centers and defense. The community remains deeply divided, with long-term investors pointing to these strategic pivots as signs of maturation while active traders debate the impact of heavy short interest and the lack of traditional, large-scale commercial revenue.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Investors in this leveraged inverse semiconductor ETF are expressing significant frustration as an unprecedented, multi-week rally in the chip sector continues to erode value and trigger persistent daily losses. The community is actively debating whether this extreme market behavior indicates a bubble fueled by algorithmic manipulation or a genuine, long-term super-cycle in AI-driven demand.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow shares are experiencing a significant sell-off despite beating earnings expectations, as investors react negatively to margin pressure and geopolitical headwinds impacting growth guidance. The community is sharply divided, with many traders viewing the volatility as a major overreaction and a buying opportunity, while others are cautioning that the broader software sector is facing a structural rerating amid concerns over AI-driven disruption.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is experiencing a parabolic, historic rally driven by intense speculative demand in the semiconductor sector and significant short covering, leading to a heated community debate over whether this represents an unsustainable 'AI bubble' or a new era of market growth. While many bulls are celebrating massive double-digit gains and calling for further upside, bears are warning of an imminent, sharp correction, causing friction and active trading in both the bull and bear leveraged ETFs.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon shares are facing intense volatility and downward pressure following the announcement of a new CEO, a move that has sparked widespread skepticism among investors concerned about the company's future growth and brand relevance. While some traders view the current price as an oversold opportunity for long-term accumulation, the broader community remains divided, with active discussions focused on leadership credibility, rising market competition, and the company's struggle to regain momentum.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is currently trending as traders weigh record U.S. natural gas production and high storage levels against ongoing geopolitical uncertainty and regional conflict in the Middle East. The community is actively debating the disconnect between elevated global energy prices and the relative stagnation of domestic natural gas, with intense focus on whether seasonal inventory builds and contract rollovers will trigger a reversal or lead to further downside.

Applied Digital Corporation

Applied Digital is trending as investors rally behind a new 7.5 billion dollar AI data center lease with a major hyperscaler, significantly expanding the company's contracted revenue backlog. The community is actively debating the potential identity of this new partner, the impact of high short interest on future price action, and the company's long-term growth trajectory within the AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CERo Therapeutics Holdings (CERO) announced on Friday that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s lead investigational compound, CER-1236, for Acute Myeloid Leukemia (AML).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CERO">CERO stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:575/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_10_32_53_AM_png_e724743b98.webp" alt="CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="575" height="64"><figcaption>CERO's Sentiment Meter and Message Volume as of 10:33 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects a "big bounce" for the stock soon.<stembedurl>https://stocktwits.com/pharmdavid13/message/627619560</stembedurl>FDA’s Fast Track Designation is designed to accelerate the development and review of therapies for serious or life-threatening conditions with unmet medical need. The designation provides CERo with the opportunity for increased FDA interactions, potential eligibility for priority review, and the ability to submit data on a rolling basis, it <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=6780690611361163">said</a>.The new designation comes weeks after the FDA granted the experimental drug an Orphan Drug designation. The FDA's Orphan Drug program is designed to advance the development of drugs that treat rare conditions affecting 200,000 or fewer US patients annually.“These FDA designations are important additional validation with regard to the urgency of the condition as well as the potential that the agency sees in the existing data as submitted. Further, these designations help to decrease the potential time to market and provide additional benefits across the FDA process that are expected to prove both medically and financially valuable,” said CERo Therapeutics CEO Chris Ehrlich.The company is currently undertaking early-stage trials of CER-1236 in patients with acute myeloid leukemia. The study is designed to evaluate the safety and preliminary efficacy of the experimental cancer drug.Shares of the company, however, slumped 12% at the time of writing after the firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/1870404/000121390025084610/ea025606902-424b3_cero.htm">said</a> on Thursday that it recently received a letter from the Nasdaq Listing Qualifications department notifying the company that it does not comply with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market.The Nasdaq staff indicated that the company’s securities would be suspended from trading on Nasdaq and delisted on Sept. 8, 2025. The company said that it subsequently requested a hearing to appeal the determination before a panel. The hearing request will stay the suspension of the trading of the company’s common stock and delisting thereof pending such hearing, it said.The company said that it intends to submit a plan to regain compliance with the Stockholders’ Equity Requirement at the hearing. Such a plan of compliance may include an increase in stockholders’ equity through the consummation of public or private financing transactions, the company said, while adding that there can be no assurances that it will obtain a favorable decision from the hearing panel.CERO stock is down by 95% this year and by 97% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CERo Therapeutics Gets Fast Track Designation For Experimental Cancer Drug, But Stock Tumbles – Here’s What Happened

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.

Equity

The new designation was granted weeks after the FDA awarded the experimental drug an Orphan Drug designation.


Shares of Cero Therapeutics Holdings drew increased retail investor chatter on Tuesday after the company said that the FDA granted orphan drug designation to its lead candidate, CER-1236, for treating acute myeloid leukemia (AML).The stock soared 189% to $19.83&nbsp;in the regular session, but fell by 15% in after-hours trading.The Phase 1/1b, open-label, multi-center clinical trial will assess the safety and initial efficacy of CER-1236 in patients with relapsed or refractory AML, remission with measurable residual disease, or newly diagnosed with TP53-mutated MDS/AML or AML.The study will include a dose escalation to determine the recommended Phase 2 dose and an expansion phase.Major objectives include the frequency of adverse events, dose-limiting toxicities, estimated overall and complete response rates, and measurable residual disease. Minor objectives include pharmacokinetics.The company said CER-1236 is designed to engineer a patient’s T cells to use phagocytic mechanisms — or target-cell “eating” — in addition to T cell destruction mechanisms.The Orphan Drug designation includes FDA assistance in clinical trial design, grants, a waiver of drug application fees, and seven years of market exclusivity upon approval.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they had accumulated shares from $8 to $15 and were still holding 4,700 shares, undecided on whether to carry the position overnight.&nbsp;<stembedurl>https://stocktwits.com/Dansaidso/message/618224240</stembedurl>Another user pointed to the stock's sharp gains, suggesting that after-hours moves were less meaningful for low-float names like Cero, which they believed could see additional upside.<stembedurl>https://stocktwits.com/SK444/message/618231176</stembedurl>Cero stock has declined 83.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Light micrograph of a section through a transitional cell carcinoma (TCC, cancer) of the bladder wall. | Image source: Getty Images

Cero Therapeutics Rockets On FDA Orphan Drug Status For Blood Cancer Drug; Retail Bulls Feel Stock 'Still Has A Few Pumps Left'

CER-1236 is designed to engineer T cells with phagocytic, or target-cell "eating," functions alongside traditional cancer-killing mechanisms. 

Biotech company CERo Therapeutics Holdings, Inc. (CERO) on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7625589476402466">announced</a> an agreement with the University of California Davis to manufacture its lead compound, CER-1236, which will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia (AML).The company said that the first patient is expected to be dosed in the first half of 2025.CEO Chris Ehrlich highlighted UC Davis’ precision and compliance in manufacturing, which is critical for the successful development and execution of clinical trials.“The manufacturing of product is among the final steps necessary to have completed prior to patient dosing, and we are looking forward to continuing to drive the process forward,” he said.The U.S. Food and Drug Administration (FDA) cleared the company’s application for phase 1 clinical trials of the compound in November.Earlier this month, during a scientific conference in San Diego, the company demonstrated that CER-1236 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cero.bio/press-release?storyId=5472816266845157">treated</a> ovarian cancer cells without generating toxicity in animals.On Stocktwits, retail sentiment continues to trend in the ‘bullish’ territory (63/100) while message volume remains high.<figure class="image"><img style="aspect-ratio:811/177;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_03_19_101142_png_18b82101f9.webp" alt="CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits" width="811" height="177"><figcaption>CERo Therapeutics' Sentiment Meter and Message Volume as of 10:10 a.m. ET on March 19, 2025 | Source: Stocktwits</figcaption></figure>At the end of 2024, the company faced delisting risks after its shares traded below Nasdaq’s minimum bid price requirement. Earlier this year, it announced a one-for-hundred reverse stock split of its common stock to increase its market price.In February, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cero.bio/press-release?storyId=7680160497345168">raised $5 million</a> through a public offering.<a href="https://stocktwits.com/symbol/CERO">Shares of CERo</a> have dropped by over 80% year-to-date and about 100% in the past 12 months. On Wednesday morning, the stock opened over 2% lower.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/morgan-stanley-in-spotlight-after-reports-of-workforce-reduction/ch7kWQlRb2g">Morgan Stanley In Spotlight After Reports Of Workforce Reduction, Retail’s Yet To React</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic picture shows a hand holidng a capsule on 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

CERo Therapeutics Partners With University Of California Davis For Manufacturing Lead Compound For Treating Cancer: Retail Stays Bullish

The compound will be used in the company’s Phase 1 clinical trial for Acute Myeloid Leukemia, with the first patient expected to be dosed in the first half of 2025.

U.S. biotech stocks, particularly small and mid-cap companies, remained a focal point for retail investors in 2024 despite significant volatility.&nbsp;Collectively, biotech stocks on U.S. bourses have garnered over 3.3 million watchers on Stocktwits.&nbsp;Here are the top five biotech stocks that saw the most significant surge in new followers this year:CERo Therapeutics Holdings Inc. (CERO): +44544% WatchersThis immunotherapy company develops engineered T-cell therapeutics for cancer. <a href="https://stocktwits.com/symbol/CERO">CERO</a> saw major retail interest following the FDA’s clearance of its lead compound, CER-1236, for Phase 1 clinical trials after an earlier clinical hold. The company went public via a SPAC merger in February and has lost 99% of its value this year.Psyence Biomedical Ltd. (PBM): +6741% WatchersKnown for developing natural psilocybin products for treating psychological trauma, PBM gained attention for positive results from its Phase IIb trial in adjustment disorder treatment for terminal cancer patients.&nbsp;Its&nbsp;shares have also dropped 99% this year since the company’s March SPAC debut.Azitra Inc. (AZTR): +2365% WatchersSpecializing in dermatological therapies using engineered proteins and live biotherapeutic products, AZTR drew attention for securing&nbsp;a fast track designation for ATR-04 and other multiple&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-are-azitra-shares-trending-on-wednesday/c7r4UW0RbE">patents</a>. Its stock value has plunged more than 99% since its debut in June last year.Immuneering Corporation (IMRX): +2248% WatchersFocused on oncology, IMRX’s lead program, IMM-1-104, received FDA orphan drug designation for pancreatic cancer and fast-track status to treat certain melanoma patients, and is currently in a Phase 2a trial. <a href="https://stocktwits.com/symbol/IMRX">IMRX shares</a> have declined over 70% year-to-date.NKGen Biotech Inc. (NKGN): +1260% WatchersNKGN develops autologous and CAR-NK cell therapies. Its SNK01 natural killer cell therapy for Alzheimer’s disease showed promising results, with 90% of patients maintaining or improving cognitive function. The candidate was cleared to progress into phase 2 clinical development, which will involve a larger group of 30 patients with moderate Alzheimer's disease. Shares, however, have fallen more than 66% this year.Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments, positioning them as key biotech names to watch heading into 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024

Despite their stock price struggles, these companies have captivated retail investors with groundbreaking therapies and promising clinical developments.

CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. Its platform is designed to redirect patient-derived T cells to eliminate tumors, creating Chimeric Engulfment Receptor T (CER-T) cells used for spanning hematological malignancies and solid tumors. The company was founded on June 8, 2021 and is headquartered in Oakland, CA.

Current Price	$0.0301
Prev Close	$0.0322
Open	$0.035
Dividend Yield	0.00%
50-Day Moving Average	$0.0355
Beta	3.85
Avg. Volume	344,421.86
PE Ratio	0.00

52-Week High	$28.40
52-Week Low	$0.02
Market Capitalization	$1.19M
EPS (Annual)	-$22.58
Price to Book	-0.05
Revenue Per Employee	$0.00

CERO
CERo Therapeutics Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CERO News

CEROCERo Therapeutics Holdings Inc